Personal tools
You are here: Home / Labs / Animal Cell Technology Unit / Invited Speakers

Invited Speakers


  • Prof Dr José (Joe) Santos
    Innovation: Composing Across Confines
    March 16th 2020 


  • Prof Dr Brandon DeKosky
    Large-scale functional analysis of natively paired antibody heavy light chain repertoires
    November 20th 2019
  • Prof Dr José Manuel Otero
    Disruptive engineering of viral immunotherapies to create a world free of cancer
    October 23rd 2019
  • Prof Dr Renata Stripecke
    Re-Generando: Gene modified dendritic cells and CAR-T cells to rebuild the immune system
    October 8th 2019
  • Prof Dr Harald Dinter
    Challenges of the pharmaceutical industry and its implications for collaborators
    May 13th 2019
  • Prof Dr Joost Sluijter
    Therapeutics for myocardial repair – moving forward?
    September 14th 2018


  • Dr. Jörg Weiske, Head of Protein Technologies 1, Research & Development, Pharmaceuticals at Bayer AG
    Cellular Thermal Shift Assay (CETSA) - Case study @ Protein Technologies (Bayer AG)
    May 17th 2018
  • Professor Tom L. Blundell, Cambridge University, UK
    Structure-guided Fragment-based Drug Discovery for Cancer and Tuberculosis: Fighting the Emergence of Resistance
  • Prof. Alois Jungbauer, Department of Biotechnology, BOKU, Vienna, Austria
    Separation and Quantification of Virus-like Particles from other extra cellular particles
    March 15th 2018
  • David Naveh, Ph.D., MBA, CEO Hemogem, ex- VP and ex-CTO of Bayer Biological Products Worldwide
    Development of Biological Therapeutics for Health and Financial Value Creation - The Pharma Perspective
    March 7th 2018
  • Monique M. van Oers, Laboratory of Virology, Wagninngen University, the Netherlands
    Proteins Required for Baculovirus Particle Formation: Relevance for the Development of a Baculovirion-Free Expression System
    March 7th 2018
  • Professor Mike Betenbaugh, Johns Hopkins University, USA
    Glycoengineering in CHO cells: Glyco Control-Inside and Out
    February 5th 2018
  • Andreas Busch, Head of Drug Discovery - Bayer Pharmaceuticals
    Addressing unmet medical needs: Key drivers for Drug Discovery at Bayer
    January 8th 2018
  • Dr. Manel Cascalló, VCN Biosciences SL, Spain
    Oncolytic adenoviruses expressing hyaluronidase: from bench to patients
    January 8th 2018
  • Dr. Eda Machado, St. Jude Children's Research Hospital, Memphis, Memphis, Tennessee USA
    Regulated lysosomal exocytosis, an unconventional pathway in cancer progression
    January 8th 2018
  • Dr. Andreas Wilmen, Protein Engineering & Assays 2, Bayer AG
    Cardiovascular Research at Bayer
    January 8th 2018
  • Dr Hansjörg Hauser, Department of Scientific Strategy, Helmholtz Centre for Infection Research (HZI)
    Viral defence by interferons: A closer look to single cells in populations
    January 8th 2018


  • William M. Miller, Chemical and Biological Engineering, Northwestern University Evanston, USA
    A Uniform-Shear-Rate Microfluidic Bioreactor for Real-Time Analysis of Proplatelet Formation and Rapidly-Released Platelets
    June 21st 2017
  • Alain Bernard, Biopharma Executive Advisor, Independent advisor to pharma executives · Institut National Agronomique Paris-Grignon
    Knowledge Management
    April 12th 2017
  • Felipe Prosper, Director of Hematology and Cell Therapy, Clinica Universidad de Navarra
    Drug and cell delivery systems for cardiac repair
    February 7th 2017
  • Simone Kardinahl, Head of Cell & Protein Sciences, Biologics Research, Bayer AG
    DD Biologics – an overview on challenges and opportunities
    January 31st 2017


  • Brian Murphy, Celgene Cellular Therapeutics, USA
    Quality by Design and Phase Appropriate Development for Cell Therapies
    November 28th 2016
  • Thorsten Lorenz, Novartis Pharma AG, Basel, Switzerland
    Developability Assessment of therapeutic Antibodies - A concept for early Lead Selection
    May 31st 2016
  • Katey Owen, Deputy Director for Vaccines Development (CMC), Bill & Melinda Gates Foundation
    Vaccine development and manufacturing for those most in need of vaccines
    April 29th 2016


  • Philippe Couttet, Novartis Institutes of Biomedical Research in Basel, Switzerland
    microRNAs as biomarker of drug-induced tissue injury
    December 3rd 2015
  • Uwe Marx, CEO, TissUse GmbH
    Humans-on-a-chip” – a paradigm shift in substance testing?!
    November 17th 2015
  • Eytan Abraham, Head of Cell Therapy Research & Technology, Lonza, USA
    Stem Cells and Cell Therapy at LONZA
    July 13th 2015
  • Hitto Kaufmann, Vice President Technology and Development at Sanofi Biologics, Germany
    Innovation in Biologics Manufacturing
    May 27th 2015
  • Thomas Pietzonka, NIBR Biologics Center, Basel
    Changing the Practice of Medicine - Novartis Institutes for Biomedical Research
    May 4th 2015
  • Matthias Frech, MERCK KGaA
    Biophysical Methods in Drug Discovery: Combination is Key. The Project Kinetics for Drug Discovery
    February 27th 2015
  • Roger-Marc Nicoud, NOVASEP HOLDING S.A.S., FRANCE
    The amazing ability of continuous chromatography to adapt to a moving environment
    February 12th 2015


  • Carlos Augusto Pereira, Instituto Butantan, Laboratorio de Imunologia Viral, São Paulo, Brazil
    Vectors carrying heterologous RNA for designing new viral vaccines
    October 23rd 2014
  • Christof von Kalle, MD, PhD, National Center for Tumor Diseases (NCT), Heidelberg
    Translational Oncology – the National Center for Tumor Diseases
    October 17th 2014
  • Rene Hoet, Heiner Apeler, Lars Linden, Beate Müller-Tiemann, BAYER HEALTHCARE, Global Biologics, Germany
    Protein Biopharmaceuticals @ Bayer: From Discovery to Development
    July 3rd 2014
    The ILRI Vaccine Biosciences program and improved vaccines for the control of East Coast fever in cattle
    May 16th 2014


  • Marc Peschanski, I-STEM (INSERM/UEVE 861, AFM), Evry – France
    Harnessing pluripotent stem cells for pharmacology
    July 18th 2013


  • Muntasir Mamun Majumder, FIMM, Institute for Molecular Medicine Finland
    An individualized system medicine platform to guide treatment decisions for therapy-resistant Acute Myeloid Leukemia
    June 21st 2012
  • Joachim Klein, Technische Universtat Braunschweig, Germany (jUb.), President, Braunschweig Academy of Sciences, Germany
    Not all chemicals are created equal: The potential of biobased processes and products
    June 1st 2012


  • John G. Aunins, Visiting Professor, ITQB, Merck Sharp & Dohme, West Point, New Jersey, USA
    Some Perspectives on Vaccines, Biologicals, and the Pharmaceutical Industry
    November 15th 2011
  • Uwe Marx & Mark Rosowski, Technische Universität Berlin, Institute of Biotechnology - Department of Medical Biotechnology
    Vascularized multi-organ systems – the next level of engineering human biology in vitro
    August 4th 2011
  • Isabelle Knott, Director, Head of Cell Culture Development, GlaxoSmithKline Biologicals S.A., Rixensart, Belgium
    Cervarix: first human vaccine manufactured with baculovirus expression system
    July 12th 2011
  • Héla Kallel, Head, Bioprocess Development Unit, Institut Pasteur de Tunis
    Bioprocess development activities at Institut Pasteur of Tunis
    June 28th 2011
  • Regina Grillari, PhD, Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria
    The importance of peeing earnest: urine derived cells as model systems in biology and biomedicine
    June 17th 2011
  • Christian Manzke & Etienne Evrard MD, Sartorius Stedim Biotech GmbH – B. Braun AG -Goettingen / Melsungen
    Bioprocess integrated solutions
    Abril 27th 2011
  • Brian Lee MD, President, PBS Biotech, Inc, California, EUA
    Mixing methodologies in single use bioreactors - A comparative analysis of consistency across scale
    Abril 4th 2011
  • Aleš Štrancar MD PhD, BIA Separations, Ljubljana
    Monolithic chromatography supports – technology platform for the analysis and production of new generation of drug candidates like plasmid DNA and viral vector particles
    March 21st 2011
  • Wilfried Bakker MD, Netherlands Vaccine Institute (NVI/RIVM)
    Development and Technology Transfer for Viral Vaccines
    March 15th 2011
  • Leo van der Pol MD PhD, Netherlands Vaccine Institute (NVI/RIVM)
    Overview of Vaccine Process Development at RIVM
    March 15th 2011
  • Marc Peschanski MD, Scientific Director, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-STEM, INSERM/UEVE) Evry, France
    Pathological modeling, drug discovery and toxicity testing using pluripotent stem cells
    March 2nd 2011
  • Leo van der Pol MD
    Overview of Vaccine Process Development at RIVM


  • Nigel Jenkins, National Institute for Cellular Biotechnology, Ireland
    Quality considerations for the production of biopharmaceuticals
    February 2nd 2010
  • Hagen von Briesen, Fraunhofer-Institute for Biomedical Engineering
    Global HIV Vaccine Research Cryorepository - GHRC
    January 29th 2010


  • Judy Lieberman, Immune Disease Institute and Program in Cellular and Molecular Medicine, Children’s Hospital Boston, Dept of Pediatrics, Harvard Medical School
    Micromanaging cell growth and differentiation
    December 16th, 2009
  • Octavio T. Ramírez, Departamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología Universidad Nacional Autónoma de México
    Bioreactor Scale-Down Studies of Temperature-Inducible Recombinant Protein Production in E. coli
    November 23th, 2009
  • Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
    Viral Vectors in Gene Therapy: Special Emphasis on Alphaviruses
    March 11th, 2009
  • Kenneth Lundstrom, PanTherapeutics, Lausanne, Switzerland
    Expression of GPCRs in Drug Discovery and Structural Biology
    March 10th, 2009
  • Catherine Brenner Jan, DR CNRS, Faculté de Pharmacie, Lausanne, Switzerland
    Signalisation et physiopathologie cardiaque INSERM U769
    February 2009


  • Anna Price, In vitro Toxicology Unit,  European Centre for the Validation of Alternative Methods,  Institute of Health and Consumer Protection, European Commission Joint Research Centre, Ispra (VA), Italy
    Re-aggregated brain cell culture as a sensitive in vitro model to evaluate developmental/adult neurotoxicity: application for regulatory requirements
    October 28th, 2008
  • Dr. Ing. Reiner Luttmann, Hamburg University of Applied Sciences, Research Center of Bioprocess Engineering and Analytical Techniques
    A comprehensive study in optimal production of Active Pharmaceutical Ingredients with Pichia pastoris
    September 12th, 2008
  • Manuel Cánovas, Department of Biochemistry and Molecular Biology B. Faculty of Chemistry. University of Murcia
    Bioprocess Optimization By Using Systems Biology
    September 11th, 2008
  • Matthew Croughan, Amgen Bioprocessing Center, Keck Graduate Institute (KGI), Claremont, CA
    The Silver Anniversary of Clinical Protein Production from Recombinant CHO Cell Culture
    June 9th, 2008

Other presentations

  • Carlos A. Pereira, Univ. Strasbourg, França and Instituto Butantan, Brasil
    Approaches for preparation of viral antigens from mammalian and insect cells
  • John Aunins, MERCK & CO, Philadelphia, EUA and ITQB/UNL, Portugal
    Adenovirus-vectored HIV vaccine development
  • Hansjörg Hauser, GBF and Univ. Braunschweig, Germany
    Cancer immune therapy using genetically modified dendritic cells
  • Eric J. Kremer, CNRS-UMR, France
  • Ursula Sonnewald, Pharmacology & Toxicology Medical School Trondheim, Norway
  • Uwe Gottschalk, Sartorius AG, Germany
  • Heiko Zimmermann, Fraunhofer IBMT, Germany
  • Catherine Brenner, CNRS-UMR, France
  • Kenneth Lundstrom, PanTherapeutics, Switzerland
  • Brian Kelley, Genentech, USA
  • Laura Palomares, México
Document Actions